New York GLP-1 Weight Loss Compliance 2026: Semaglutide, Tirzepatide & NY Prescribing Rules

Two federal dates ended the compounded GLP-1 boom that built half the weight-loss programs in New York med spas: October 2024, when the FDA removed tirzepatide from its drug shortage list, and February 21, 2025, when semaglutide came off as well.

Once a drug is off the shortage list, the federal "essentially-a-copy" rule kicks back in. Section 503A of the Food, Drug, and Cosmetic Act prohibits a state-licensed compounding pharmacy from compounding a drug that is essentially a copy of a commercially available FDA-approved product, except in narrow clinical circumstances. The shortage was the loophole. The shortage is gone.

For New York med spas, that change layers onto a state regulatory environment that already takes a hard look at weight-loss prescribing. The NY Office of the Professions and the Department of Health have both signaled that high-volume online weight-loss prescribing without a real clinical encounter is on their radar.

This guide covers what NY med spas can actually do in 2026 — what to prescribe, how to document it, where telehealth fits, and the OPMC patterns to avoid.

What Changed: The End of the Compounded GLP-1 Era

From roughly 2022 through mid-2024, FDA-approved GLP-1s were on the federal drug shortage list. That status had a specific consequence: compounding pharmacies could legally produce copies of semaglutide and tirzepatide for individual patients. Med spas across New York built entire programs on this — sourcing compounded vials at $200–$400/month versus $900–$1,300/month retail for the branded products.

Tirzepatide — Off the List October 2, 2024

The FDA declared the tirzepatide shortage resolved on October 2, 2024, after Eli Lilly confirmed that supply of Mounjaro and Zepbound had stabilized. After a brief court-extended transition window, both 503A pharmacies and 503B outsourcing facilities lost the routine ability to compound tirzepatide copies.

Semaglutide — Off the List February 21, 2025

Novo Nordisk reached supply normalization later. The FDA removed semaglutide from the shortage list on February 21, 2025. The transition for compounded semaglutide effectively ended in spring 2025, with the same outcome: 503A compounding of copies is no longer broadly permitted.

The current FDA shortage status for any GLP-1 should be verified directly at the FDA Drug Shortages database before relying on a compounding-based protocol.

What's Still Allowed

Compounding hasn't disappeared entirely. Narrow paths remain:

• Documented clinical difference: A compounded formulation that is not "essentially a copy" — for example, a clinically necessary dose strength not available in the FDA-approved product, or an ingredient combination clinically indicated for a specific patient.
• Component allergy or intolerance: A documented patient-specific clinical need (such as an inactive-ingredient allergy) supported in the chart.
• 503B outsourcing facilities: Limited compounding under stricter conditions, primarily for hospitals and clinics with documented need — not the routine commercial supply that fed med spa programs.

"My patient prefers the lower price" is not a clinical difference. "We always used compounded" is not a clinical difference. These rationales will not survive a Board review or a pharmacy audit.

What NY Med Spas Can Legally Prescribe in 2026

The Branded GLP-1 List

FDA-approved products that a NY-licensed prescriber can lawfully prescribe today:

• Semaglutide — Wegovy (weight loss indication), Ozempic (T2DM), Rybelsus (oral T2DM)
• Tirzepatide — Zepbound (weight loss), Mounjaro (T2DM)
• Liraglutide — Saxenda (weight loss), Victoza (T2DM)

Wegovy and Zepbound are the labeled-for-weight-loss options. Ozempic and Mounjaro are diabetes products that are sometimes prescribed off-label for weight management; off-label prescribing remains legal in New York when supported by a documented clinical rationale, but the chart must reflect that rationale.

Off-Label Prescribing in New York

NY does not prohibit off-label prescribing, but the standard of care still applies. If you prescribe Ozempic for a patient without diabetes, the chart needs to show why — BMI thresholds, comorbidities, prior weight-loss attempts, why a labeled product (Wegovy, Zepbound) wasn't used, and informed consent that addresses off-label use. Lack of this documentation is one of the most common findings in NY OPMC weight-loss cases.

Who Can Prescribe GLP-1s at a New York Med Spa

New York's prescribing-authority rules under Education Law §6810 apply. The provider must be:

• A New York-licensed physician (MD or DO), or
• A New York-licensed nurse practitioner (NP) acting within their certification specialty and collaboration agreement, or
• A New York-licensed physician assistant (PA) acting under physician supervision per the supervision agreement

Notably, NPs in New York must complete the 3,600-hour collaboration requirement before practicing independently under a Collaborative Relationship; until then, they prescribe under a written collaborative agreement with a NY-licensed physician. That agreement should explicitly include weight-management prescribing within its scope.

RNs cannot prescribe. They can administer GLP-1 injections under standing orders signed by a NY prescriber, but the prescribing decision — the good-faith examination, the medical necessity assessment, the chart entry — must come from a physician, NP, or PA.

The "Good Faith Examination" — What NY Requires

New York case law and Board guidance require a "good faith examination" before a prescription is issued. There is no statutory definition of exactly what that examination must include, but OPMC enforcement actions tell a clear story.

Minimum Elements Documented

1. Patient history — current medications, allergies, prior weight-loss attempts, relevant surgical history, family history
2. Anthropometrics — verified height, weight, and BMI (a self-reported value alone is not adequate when the patient could be reasonably weighed)
3. Comorbidities — Type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease, prediabetes — these establish medical necessity
4. Contraindication screen — personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN-2), pancreatitis, severe gastrointestinal disease, gastroparesis, pregnancy or pregnancy planning, severe renal or hepatic impairment
5. Mental health screen — eating disorder history, suicidality (FDA labeling for GLP-1s notes psychiatric considerations)
6. Informed consent — risks, benefits, common adverse events (nausea, vomiting, constipation), serious risks (pancreatitis, gallbladder disease, MTC warning), pregnancy considerations, off-label use if applicable
7. Treatment plan — starting dose, titration schedule, follow-up intervals, monitoring plan, criteria for dose change or discontinuation

Recommended Pre-Treatment Labs

Not statutorily required for every patient, but standard of care for a GLP-1 weight-loss program — and what NY OPMC reviewers look for in a defensible chart:

• Hemoglobin A1c
• Comprehensive metabolic panel (kidney and liver function)
• Lipid panel
• TSH (thyroid function)
• Lipase (baseline if pancreatitis history is present)
• Pregnancy test for patients of childbearing potential

Telehealth Prescribing of GLP-1s in New York

New York permits the establishment of a physician-patient relationship via telehealth under Public Health Law §2999-cc and 10 NYCRR Part 405. An in-person visit is not federally or state-required to issue a non-controlled prescription like a GLP-1.

However, telehealth does not lower the bar on the good-faith examination — it changes how the examination is conducted. The visit must still be a real clinical encounter, with synchronous audio-video where clinically appropriate.

NY Telehealth Requirements for GLP-1 Prescribing

• Synchronous interaction: Live audio-video for the initial visit. An online intake form alone is not sufficient.
• Provider identity verification: The patient must be able to verify the prescriber's identity and credentials
• Patient location at time of service: The patient must be physically present in New York at the time of the encounter (or the provider must be licensed in the patient's state)
• Informed telehealth consent: Specific consent for telehealth — separate from medical informed consent — including discussion of telehealth limitations and emergency procedures
• HIPAA-compliant platform: The video platform must support HIPAA and align with NY DOH telehealth guidance
• NY PHL §18 access: Patients have the right to access their telehealth records on request

The model that triggers NY OPMC complaints is the "5-minute intake" — a patient fills a web form, a clinician they never speak to issues a prescription, and a compounded vial ships from out of state. That model is not a good-faith examination, and OPMC has issued discipline against physicians who structured their practice this way, regardless of how many patients were behind them.

Pharmacy Partnership Rules in New York

The dispensing pharmacy is your second compliance surface. New York's Public Health Law §6810 and Education Law §6810 set out pharmacy practice and prescription requirements within the state. The NY Board of Pharmacy oversees in-state pharmacies and registers non-resident (out-of-state) mail-order pharmacies that ship into NY.

In-State Dispensing Pharmacies

An NY-licensed retail or specialty pharmacy can dispense Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda directly to your patient on a valid NY prescription. Most large chains (CVS, Walgreens, Duane Reade, independents) and weight-loss-focused specialty pharmacies meet this standard.

Out-of-State / Mail-Order Pharmacies

An out-of-state pharmacy can ship to NY patients only if it holds a current non-resident pharmacy registration with the New York Board of Pharmacy. Before partnering, verify the registration:

• Confirm registration in the NYSED Office of the Professions verification system
• Confirm the pharmacy carries the FDA-approved branded products and is not relying on compounded substitutions
• Get the registration number in writing for your file

Compounding Pharmacy Red Flags

If a pharmacy currently offers your med spa "compounded semaglutide" or "compounded tirzepatide" without a documented patient-specific clinical rationale, walk away. The legal exposure is on the prescriber as well as the pharmacy. A NY OPMC investigation can be triggered by a pharmacy board referral, and the prescription record will lead directly back to your chart.

Refills, Follow-Up, and Continued Prescribing

NY does not specify a fixed follow-up interval for weight-loss prescribing, but standard of care drives the schedule:

• First follow-up: 4 weeks after initiation — assess tolerance, side effects, weight response, dose titration
• Subsequent follow-ups: Every 4–12 weeks during titration
• Maintenance: At least every 3 months once stable
• Annual labs: Repeat A1c, kidney/liver function, lipid panel
• Discontinuation criteria: Documented in the plan — stop if weight loss less than 5% at 12 weeks at maintenance dose, intolerable side effects, contraindication develops, or pregnancy

Auto-refilling a GLP-1 for 12+ months without a follow-up encounter is a structural OPMC red flag. Build a recall workflow before you write the first prescription.

NY OPMC Overprescribing Patterns

The Office of Professional Medical Conduct enforces medical practice misconduct under Public Health Law Title II. The patterns that have produced GLP-1-related discipline in New York:

Pattern 1: Form-Driven Prescribing

The patient fills out a web form. A reviewing clinician checks boxes and signs off. There is no synchronous encounter. The chart is essentially the form. OPMC has treated this as failure to conduct a good-faith examination.

Pattern 2: Unsigned Standing Orders

A protocol document allows medical assistants or RNs to "approve" weight-loss intakes without a prescribing clinician's individualized review. Standing orders can authorize administration of an already-prescribed medication. They cannot authorize the prescribing decision.

Pattern 3: Missing Contraindication Screening

Charts that do not document the MTC/MEN-2 family-history screen, pancreatitis screen, or pregnancy screen. The black-box warning on GLP-1 labeling exists for a reason; charts that ignore it are easy targets in a Board review.

Pattern 4: Title or Specialty Mismatch

An NP whose national certification is in a non-adult population (PNP, neonatal) prescribing weight-loss medications to adult patients. Population-of-focus mismatch is an independent disciplinary finding regardless of the prescription's clinical merit.

Pattern 5: Missing Telehealth Consent

The chart contains a generic medical consent but no separate telehealth-specific consent. NY treats telehealth consent as a distinct disclosure obligation.

How NY Compares to Federal GLP-1 Standards

Most of what New York requires also tracks federal best practice. For the federal-level picture and how it applies across states, see our national GLP-1 weight-loss compliance guide. NY-specific layers on top:

• The good-faith examination doctrine is more developed in NY case law than in many states
• The non-resident pharmacy registration requirement is enforced
• OPMC enforcement is among the more active state boards on weight-loss prescribing
• Telehealth consent is treated as a discrete obligation

The Operational Checklist

If you operate a NY med spa offering GLP-1s, this is the minimum operational stack you should be able to produce on demand:

1. Written GLP-1 SOP signed by the medical director, covering eligibility, contraindications, dose titration, monitoring, and discontinuation
2. Patient assessment template with all good-faith examination elements
3. Contraindication screening checklist (MTC/MEN-2, pancreatitis, pregnancy, gastroparesis, etc.)
4. Informed consent form covering risks, benefits, off-label use, pregnancy
5. Telehealth informed consent separate from medical consent
6. HIPAA-compliant telehealth platform with synchronous audio-video
7. Pharmacy partnership documentation — copy of NY pharmacy license or non-resident registration
8. Follow-up workflow with scheduled recalls at 4 weeks, then 4–12 weeks during titration
9. Discontinuation criteria documented in the SOP
10. Adverse event log tracking nausea/GI events, suspected pancreatitis, gallbladder events
11. NP collaborative agreement (if applicable) with weight-management explicitly included in scope

For the broader NY compliance picture across all procedures, see the New York med spa compliance checklist, the NY medical director requirements, and the NY advertising rules guide. Provider-by-provider scope (who can inject what) is in the NY injection scope guide.

I-STOP, EPCS, and the PMP — What Doesn't Apply

For clarity: GLP-1 receptor agonists are not controlled substances. They are not subject to:

• I-STOP / Prescription Monitoring Program reporting (NY DOH I-STOP)
• EPCS (Electronic Prescribing of Controlled Substances) mandates
• DEA registration for the prescriber (a DEA number is needed only if the practice prescribes any controlled substance)

Electronic prescribing for GLP-1s is best practice for legibility, audit, and pharmacy efficiency, but is not legally mandated under I-STOP. If your practice also offers other weight-management drugs that are controlled (phentermine, for example, is a Schedule IV controlled substance), those are subject to I-STOP and EPCS — and that's a separate workflow.

Summary

1. The FDA removed tirzepatide (October 2024) and semaglutide (February 2025) from its drug shortage list — routine 503A compounded GLP-1s are no longer broadly legal
2. NY med spas should prescribe FDA-approved branded GLP-1s: Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda
3. A "good faith examination" is required before prescribing — BMI, comorbidities, contraindications, informed consent, treatment plan
4. Telehealth prescribing is permitted under PHL §2999-cc, but a synchronous audio-video encounter and separate telehealth consent are required
5. Out-of-state pharmacies must hold a NY non-resident pharmacy registration to ship into the state
6. OPMC has disciplined providers for form-driven prescribing, missing contraindication screens, and population-mismatch NP prescribing
7. GLP-1s are not controlled — not in I-STOP, not subject to EPCS — but documentation expectations are higher than for many non-controlled drugs

Disclaimer: This article is for educational purposes only and does not constitute legal or medical advice. GLP-1 prescribing involves federal and state regulatory considerations that change frequently. Verify current FDA shortage status and consult with a New York healthcare attorney and your medical director before establishing or modifying a weight-loss program.